Correlation between dispensed and prescribed doses of factor products for bleeding disorders: Can a small, centre-based pharmacy hit the mark?

Haemophilia

Volumn 21, Issue 2, 2015, Pages 190-195

  Croteau, S E ^a   Saxena, K ^a   Neufeld, E J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cost of care; Factor IX; Factor VIII; Haemophilia; Utilization

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR;

ADULT; ARTICLE; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BODY WEIGHT; CHILD; DRUG COST; DRUG DOSE REGIMEN; DRUG MONITORING; GROUPS BY AGE; HEMOPHILIA; HUMAN; MAJOR CLINICAL STUDY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VON WILLEBRAND DISEASE; BLOOD COAGULATION DISORDERS; UNITED STATES;

ADULT; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BOSTON; CHILD; HUMANS; PHARMACEUTICAL SERVICES; RETROSPECTIVE STUDIES;

EID: 84923100202     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12546     Document Type: Article

References (7)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
3. Auerswald G, von Depka PM, Ehlken B et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004; 10: 499-508.
4. Globe DR, Curtis RG, Koerper MA, HUGS Steering Committee . Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004; 10(Suppl 1): 63-70.
5. Gringeri A, Mantovani LG, Scalone L, Mannucci PM, COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
6. Zhou ZY, Wu J, Baker J et al. Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data. Haemophilia 2011; 17: 729-36.
7. Johnson KA, Zhou ZY. Costs of care in hemophilia and possible implications of health care reform. Hematology Am Soc Hematol Educ Program. 2011; 2011: 413-8.